WIB-Metro New York: Executive Women In Bio Launch – Lessons From 2020 and Charging Into 2021!

Affordable Networking & Training
01/28/2021
Online

Join us as the WIB-Metro New York chapter launches Executive Women In Bio (EWIB)!

Hear from four executive leaders about defining success during these unprecedented times, and what that means for 2021.
 Disclaimer: This event may be recorded. If so, there is a possibility your image and or voice may be a part of that recording. If you do not wish for your image to be included please turn off your camera.

 Program

4:00 p.m. – 4:15 p.m.: Event Introduction
4:15 p.m. – 5:15 p.m.: Panel Discussion
5:15 p.m. – 5:30 p.m.: Q&A

Speaker Bios

Corinne Epperly, MD, MPH, SVP Strategy and Operations at Iovance Biotherapeutics, Inc.
Corinne is an Operational Oncology Executive, Physician, and Scientist with 20 years of Clinical and Commercial Experience, including 14 years in the Biotech and Biopharma Industries and 6 years in Medicine including key scientific and management roles in immuno-oncology drug development, designing and running clinical trials, strategy, operations, financing, commercialization, and business development. She has a proven track record in M&A and partnerships and is launch lead for OPDIVO in multiple indications at BMS. As Chief Operating Officer, Corinne led clinical operations and delivered transformative financial results at VBL Therapeutics. Her expertise spans leading business operations, multibillion-dollar global transactions and negotiations, investor relations, commercial and strategic planning, and execution.

Kinnari Patel, PharmD, MBA, COO & Executive Vice President of Development at Rocket Pharmaceuticals
Kinnari is seeking gene therapy cures for devastating diseases and is inspired by patient unmet medical need and transformative scientific innovation. She is championing change through authentic leadership and fostering a culture of trust, curiosity, and generosity to elevate! Kinnari has fifteen years of rare disease Research & Development experience including in Regulatory Science, Pharmacovigilance, Policy and Quality Compliance gained at leading pharmaceutical companies including AstraZeneca, Bristol-Myers Squibb, Novartis, Hoffmann La-Roche, and Pfizer.

She has led both small molecule and biologic development programs from Phase I through Phase IV across multiple therapeutic areas including immuno-oncology, oncology, respiratory, virology, transplantation and metabolism. Most notably, Kinnari has worked on Opdivo (nivolumab) from Phase I through BLA filing for metastatic melanoma, RCC and NSCLC, submitted and gained approval of Myalept (metreleptin) for ultra-rare lipodystrophy disease, and submitted Valcyte® (valganciclovir hydrochloride) NDA for prevention of cytomegalovirus disease in pediatric kidney and heart transplant patients.

Karen LaRochelle, Company Strategist, Venture Partner and Board Member
Karen is a biopharma transactions leader and strategist with over 25 years of experience in biotechnology and pharma. She is responsible for over 50 executions spanning research, development and commercial and $4 billion of transformative biotechnology sell-side collaborations. Several have exceeded $100 million upfront payments and $1 billion of milestones including BMS, WindMIL Therapeutics, PsiOxus Therapeutics, Exelixis, and Ovid Therapeutics, plus an acquisition exit for Chase Pharmaceuticals.
Karen currently holds a dual role with industry and venture capital as Senior Vice President, Corporate & Business Development of WindMIL Therapeutics, responsible for facilitating business growth, defining partnering strategy and spearheading partnerships. She is also as a Venture Partner for Advent Life Sciences LLP and advises various life science companies in the Advent Life Sciences portfolio including Zikani Therapeutics.

Melissa Epperly, CFO at Zentalis Pharmaceuticals
Melissa is a Senior Financial Operating Executive with life sciences corporate development and financial expertise that she gained at R-Pharm US, Anchorage Capital, Goldman Sachs, Bain & Company and Morgan Stanley. She has extensive experience strategically building and improving operations as a leader, an active owner and board member. Melissa brings focus and energy working hand-in-hand with senior teams and portfolio managers to create solutions and build growth companies. With a multifaceted background she has a differentiated, problem-solving approach and perspective to tackling business challenges, quickly identifying critical value creation levers and developing strategies to realize them.

Pricing Information

  • Members: Free
  • Non-Members*: $30

*To access the Member rate, please click here to purchase a WIB membership.

Special Pricing

Members can register guests at member pricing.

Maximum Capacity

100

Register Now

Comment